AP NEWS
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
PRESS RELEASE: Paid content from Globe Newswire
Press release content from Globe Newswire. The AP news staff was not involved in its creation.

Market Trends Toward New Normal in Colgate-Palmolive, Nucor, NeoPhotonics, Piper Jaffray Companies, The Ensign Group, and Fortress Biotech — Emerging Consolidated Expectations, Analyst Ratings

April 3, 2019

NEW YORK, April 03, 2019 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Capital Review released its latest key findings for all current investors, traders, and shareholders of Colgate-Palmolive Company (NYSE:CL), Nucor Corporation (NYSE:NUE), NeoPhotonics Corporation (NYSE:NPTN), Piper Jaffray Companies (NYSE:PJC), The Ensign Group, Inc. (NASDAQ:ENSG), and Fortress Biotech, Inc. (NASDAQ:FBIO), including updated fundamental summaries, consolidated fiscal reporting, and fully-qualified certified analyst research.

Complimentary Access: Research Reports

Full copies of recently published reports are available to readers at the links below.

CL DOWNLOAD: http://Capital-Review.com/register/?so=CL NUE DOWNLOAD: http://Capital-Review.com/register/?so=NUE NPTN DOWNLOAD: http://Capital-Review.com/register/?so=NPTN PJC DOWNLOAD: http://Capital-Review.com/register/?so=PJC ENSG DOWNLOAD: http://Capital-Review.com/register/?so=ENSG FBIO DOWNLOAD: http://Capital-Review.com/register/?so=FBIO

(You may have to copy and paste the link into your browser and hit the [ENTER] key)

The new research reports from Capital Review, available for free download at the links above, examine Colgate-Palmolive Company (NYSE:CL), Nucor Corporation (NYSE:NUE), NeoPhotonics Corporation (NYSE:NPTN), Piper Jaffray Companies (NYSE:PJC), The Ensign Group, Inc. (NASDAQ:ENSG), and Fortress Biotech, Inc. (NASDAQ:FBIO) on a fundamental level and outlines the overall demand for their products and services in addition to an in-depth review of the business strategy, management discussion, and overall direction going forward. Several excerpts from the recently released reports are available to today’s readers below.

-----------------------------------------

Important Notice: the following excerpts are not designed to be standalone summaries and as such, important information may be missing from these samples. Please download the entire research report, free of charge, to ensure you are reading all relevant material information. Percentage calculations are performed after rounding. All amounts in millions (MM), except per share amounts.

-----------------------------------------

COLGATE-PALMOLIVE COMPANY (CL) REPORT OVERVIEW

Colgate-Palmolive’s Recent Financial Performance

For the three months ended December 31st, 2018 vs December 31st, 2017, Colgate-Palmolive reported revenue of $3,811.00MM vs $3,892.00MM (down 2.08%) and analysts estimated basic earnings per share $0.71 vs $0.38 (up 86.84%). For the twelve months ended December 31st, 2018 vs December 31st, 2017, Colgate-Palmolive reported revenue of $15,544.00MM vs $15,454.00MM (up 0.58%) and analysts estimated basic earnings per share $2.76 vs $2.30 (up 20.00%). Analysts expect earnings to be released on April 26th, 2019. The report will be for the fiscal period ending March 31st, 2019. The reported EPS for the same quarter last year was $0.74. The estimated EPS forecast for the next fiscal year is $3.01 and is expected to report on January 24th, 2020.

To read the full Colgate-Palmolive Company (CL) report, download it here: http://Capital-Review.com/register/?so=CL

-----------------------------------------

NUCOR CORPORATION (NUE) REPORT OVERVIEW

Nucor’s Recent Financial Performance

For the three months ended December 31st, 2018 vs December 31st, 2017, Nucor reported revenue of $6,295.89MM vs $5,092.33MM (up 23.63%) and analysts estimated basic earnings per share $2.06 vs $1.21 (up 70.25%). For the twelve months ended December 31st, 2018 vs December 31st, 2017, Nucor reported revenue of $25,067.28MM vs $20,252.39MM (up 23.77%) and analysts estimated basic earnings per share $7.44 vs $4.11 (up 81.02%). Analysts expect earnings to be released on April 18th, 2019. The report will be for the fiscal period ending March 31st, 2019. Reported EPS for the same quarter last year was $1.17. The estimated EPS forecast for the next fiscal year is $5.53 and is expected to report on February 4th, 2020.

To read the full Nucor Corporation (NUE) report, download it here: http://Capital-Review.com/register/?so=NUE

-----------------------------------------

NEOPHOTONICS CORPORATION (NPTN) REPORT OVERVIEW

NeoPhotonics’ Recent Financial Performance

For the three months ended December 31st, 2018 vs December 31st, 2017, NeoPhotonics reported revenue of $91.10MM vs $76.87MM (up 18.52%) and analysts estimated basic earnings per share -$0.14 vs -$0.32. For the twelve months ended December 31st, 2018 vs December 31st, 2017, NeoPhotonics reported revenue of $322.54MM vs $292.89MM (up 10.12%) and analysts estimated basic earnings per share -$0.97 vs -$1.23. Analysts expect earnings to be released on May 14th, 2019. The report will be for the fiscal period ending March 31st, 2019. Reported EPS for the same quarter last year was -$0.40. The estimated EPS forecast for the next fiscal year is -$0.02 and is expected to report on February 27th, 2020.

To read the full NeoPhotonics Corporation (NPTN) report, download it here: http://Capital-Review.com/register/?so=NPTN

-----------------------------------------

PIPER JAFFRAY COMPANIES (PJC) REPORT OVERVIEW

Piper Jaffray Companies’ Recent Financial Performance

For the three months ended December 31st, 2018 vs December 31st, 2017, Piper Jaffray Companies reported revenue of $224.37MM vs $236.08MM (down 4.96%) and basic earnings per share $1.43 vs -$3.38. For the twelve months ended December 31st, 2018 vs December 31st, 2017, Piper Jaffray Companies reported revenue of $784.44MM vs $874.92MM (down 10.34%) and analysts estimated basic earnings per share $3.78 vs -$5.07. Analysts expect earnings to be released on April 26th, 2019. The report will be for the fiscal period ending March 31st, 2019. The reported EPS for the same quarter last year was $1.38. The estimated EPS forecast for the next fiscal year is $7.10 and is expected to report on February 7th, 2020.

To read the full Piper Jaffray Companies (PJC) report, download it here: http://Capital-Review.com/register/?so=PJC

-----------------------------------------

THE ENSIGN GROUP, INC. (ENSG) REPORT OVERVIEW

The Ensign Group’s Recent Financial Performance

For the three months ended December 31st, 2018 vs December 31st, 2017, The Ensign Group reported revenue of $537.78MM vs $487.71MM (up 10.27%) and analysts estimated basic earnings per share $0.51 vs $0.21 (up 142.86%). For the twelve months ended December 31st, 2018 vs December 31st, 2017, The Ensign Group reported revenue of $2,040.66MM vs $1,849.32MM (up 10.35%) and analysts estimated basic earnings per share $1.78 vs $0.79 (up 125.32%). Analysts expect earnings to be released on May 1st, 2019. The report will be for the fiscal period ending March 31st, 2019. The reported EPS for the same quarter last year was $0.43. The estimated EPS forecast for the next fiscal year is $2.32 and is expected to report on February 5th, 2020.

To read the full The Ensign Group, Inc. (ENSG) report, download it here: http://Capital-Review.com/register/?so=ENSG

-----------------------------------------

FORTRESS BIOTECH, INC. (FBIO) REPORT OVERVIEW

Fortress Biotech’s Recent Financial Performance

For the three months ended December 31st, 2018 vs December 31st, 2017, Fortress Biotech reported revenue of -$156.07MM vs -$125.02MM and analysts estimated basic earnings per share -$0.58 vs -$0.21. For the twelve months ended December 31st, 2018 vs December 31st, 2017, Fortress Biotech reported revenue of $26.88MM vs $17.25MM (up 55.88%) and analysts estimated basic earnings per share -$1.94 vs -$1.61. Analysts expect earnings to be released on May 9th, 2019. The report will be for the fiscal period ending March 31st, 2019. The reported EPS for the same quarter last year was -$0.49. The estimated EPS forecast for the next fiscal year is -$2.49 and is expected to report on March 16th, 2020.

To read the full Fortress Biotech, Inc. (FBIO) report, download it here: http://Capital-Review.com/register/?so=FBIO

-----------------------------------------

ABOUT CAPITAL REVIEW

Capital Review is a nationally recognized publisher of financial analysis, research reports, and exclusive market reporting. Institutional investors, registered brokers, professional traders, and personal investment advisers rely on Capital Review to quantify public company valuations, discover opportunity across asset classes, stay informed about market-moving events, and read exclusive analysis of important material developments. With 14 offices worldwide, Capital Review staffs and manages certified and registered financial professionals, including Chartered Financial Analyst® (CFA®) designation holders and FINRA® BrokerCheck® certified individuals with current and valid CRD® number designations, to enable continuous coverage of topics relevant to its regular active reader base.

REGISTERED MEMBER STATUS

Capital Review’s oversight and audit staff are registered analysts, brokers, and/or financial advisers (“Registered Members”) working within Equity Research, Media, and Compliance departments. Capital Review’s roster includes qualified CFA® charterholders, licensed securities attorneys, and registered FINRA® members holding duly issued CRD® numbers. Current licensed status of several Registered Members at Capital Review have been independently verified by an outside audit firm, including policy and audit records duly executed by Registered Members. Complaints, concerns, questions, or inquiries regarding this release should be directed to Capital Review’s Compliance department by Phone, at +1 (410) 280-7496, or by E-mail at compliance@Capital-Review.com.

LEGAL NOTICES

Information contained herein is not an offer or solicitation to buy, hold, or sell any security. Capital Review, Capital Review members, and/or Capital Review affiliates are not responsible for any gains or losses that result from the opinions expressed. Capital Review makes no representations as to the completeness, accuracy, or timeliness of the material provided and all materials are subject to change without notice. Capital Review has not been compensated for the publication of this press release by any of the above mentioned companies. Capital Review is not a financial advisory firm, investment adviser, or broker-dealer, and does not undertake any activities that would require such registration. For our full disclaimer, disclosure, and terms of service please visit our website.

Media Contact: Morena Zambada, Media Department Office: +1 (410) 280-7496 E-mail: media@Capital-Review.com

© 2019 Capital Review. All Rights Reserved. For republishing permissions, please contact a partner network manager at partnership@Capital-Review.com.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

FINRA®, BrokerCheck®, and CRD® are registered trademarks owned by Financial Industry Regulatory Authority, Inc.